Results 51 to 60 of about 4,564,900 (257)

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease

Molecular Oncology, EarlyView.
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park, Kyongman An, Gyeonghwa Kim, Soo‐Nyun Choi, Hong‐Ki Lee, Keun Hur, Kyu‐Shik Jeong   +6 more
wiley   +1 more source

Schematic diagram showing the possible mechanism of anti-TNF-α therapy in polycystic ovary syndrome (PCOS).

, 2019
Persistent exposure to androgen promoted the secretion of TNF-α and other inflammatory factors. TNF-αsignificantly upregulated CYP17A1 and downregulated CYP19A1, the key enzymes involved in the synthesis and conversion of androgens, leading to the ...
Xie Yidong (6807866), Xu Wenming (652821), Zuo Tao (6807875), Zhang Xueguang (6807869), Qin Lang (2902367), Wu Sixian (6807872)   +5 more
core   +1 more source

Assessment of thyroid gland disorders in patients with psoriatic arthritis after anti-tumor necrosis factor therapy

Egyptian Rheumatology and Rehabilitation
Objectives To evaluate the effect of anti-tumor necrosis factor (anti-TNF) therapy on thyroid gland functionality and morphological characteristics in anti-TNF naïve psoriatic arthritis (PsA) patients.
Rehab Mahmoud Salem, Heba Ahmed Almokadem, Rania Elsaied Elkholy, Thanaa F. Mansour, Yousra Fouad Mohamed Rashad, Radwa H Shalaby   +5 more
doaj   +1 more source

Anti‐TNF‐induced lupus in patients with inflammatory bowel disease

JGH Open, 2020
Background and Aims Anti‐Tumor Necrosis Factor (TNF)‐induced lupus (ATIL) is a distinct clinical entity, increasingly recognized in patients with inflammatory bowel disease treated with anti‐TNF therapy.
Sherman Picardo, Kenji So, Kannan Venugopal   +2 more
doaj   +1 more source

PANoptosis in the pathogenesis of myelodysplastic syndromes

Molecular Oncology, EarlyView.
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla, Jyoti Lamichhane, Cameron Lewis, Peter Breslin, Jiwang Zhang   +4 more
wiley   +1 more source

Immunological Changes in Peripheral Blood of Ankylosing Spondylitis Patients during Anti-TNF-α Therapy and Their Correlations with Treatment Outcomes

Journal of Immunology Research, 2021
Tumor necrosis factor-α (TNF-α) inhibitors are the main types of biological conventional synthetic disease-modifying antirheumatic drugs and have efficacy in treating ankylosing spondylitis (AS) which is not sensitive for nonsteroidal anti-inflammatory ...
Rongjuan Chen, Hongyan Qian, Xiaoqing Yuan, Shiju Chen, Yuan Liu, Bin Wang, Guixiu Shi   +6 more
doaj   +1 more source

Predictive and prognostic biomarkers of Bacillus Calmette‐Guérin therapy failure in bladder cancer patients: A systematic review

Molecular Oncology, EarlyView.
High‐risk bladder cancer is typically treated with Bacillus Calmette‐Guérin (BCG), but 30–40% of patients relapse. No FDA‐ or CE‐approved biomarkers currently predict or prognosticate BCG failure. We systematically reviewed the literature and identified 72 eligible studies, revealing several promising biomarkers associated with BCG treatment response ...
Rui Ribeiro‐Pereira, Ana Teixeira‐Marques, Rui Freitas, João A Carvalho, Sara Monteiro‐Reis, Giorgio I. Russo, Rui Henrique, Carmen Jerónimo   +7 more
wiley   +1 more source

Anti-TNF-α plasma level and anti-drug antibodies.

, 2016
(A) Adalimumab concentration in plasma from patients with psoriasis who respond (R) or do not respond (NR) to therapy ...
Federica Ferrari (3391226), Marcello Pinti (295127), Andrea Cossarizza (295123), Marco Manfredini (3391214), Milena Nasi (295128), Giuseppe Albertini (3391220), Regina Bartolomeo (3391223), Elena Bianchini (686335), Carlo Salvarani (412600), Lara Gibellini (117504), Giovanni Pellacani (266366), Sara De Biasi (295129), Anna Iannone (2339785), Antonella Fabiano (3391217), Tommaso Trenti (179891)   +14 more
core   +1 more source

Public versus Private Drug Insurance and Outcomes of Patients Requiring Biologic Therapies for Inflammatory Bowel Disease

Canadian Journal of Gastroenterology and Hepatology, 2017
Background. Antitumor necrosis factor (anti-TNF) therapy is a highly effective but costly treatment for inflammatory bowel disease (IBD). Methods. We conducted a retrospective cohort study of IBD patients who were prescribed anti-TNF therapy (2007–2014 ...
Amir Rumman, Roberto Candia, Justina J. Sam, Kenneth Croitoru, Mark S. Silverberg, A. Hillary Steinhart, Geoffrey C. Nguyen   +6 more
doaj   +1 more source

Effect of Anti-TNF Therapy on Mucosal Apoptosis Genes Expression in Crohn's Disease

Frontiers in Immunology, 2021
Crohn's disease (CD) is a chronic immune-mediated disorder for which there is not a fully effective treatment. Moreover, biological therapy with anti-tumor necrosis factor-α (anti-TNF-α) monoclonal antibodies leads to an effective response in only 60–70%
Liliana Lykowska-Szuber, Michal Walczak, Marzena Skrzypczak-Zielinska, Joanna Suszynska-Zajczyk, Kamila Stawczyk-Eder, Katarzyna Waszak, Piotr Eder, Anna Wozniak, Iwona Krela-Kazmierczak, Ryszard Slomski, Agnieszka Dobrowolska   +10 more
doaj   +1 more source